To find the most relevant journal, please insert appropriate keyword to facilitate search.
Search Results: CHDDT
Cardiovascular & Hematological Disorders-Drug Targets
ISSN: 1871-529X (Print)
eISSN: 2212-4063 (Online)
Scopus
CiteScore:
CiteScore:
1.9
Aims and Scope:Cardiovascular & Hematological Disorders-Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of in-depth/mini reviews, original research articles, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.
Editor-in-Chief:
Pietro Scicchitano Department of Cardiology
Hospital "F. Perinei"
Bari
Italy
Hospital "F. Perinei"
Bari
Italy
Special Issues With Active Call for Papers
Submission closes on: Jul 01, 2025
Effective Lowering pf Lipoprotein (a) – A new Frontier in Cardiovascular Risk Reduction
Elevated lipoprotein(a) (Lp[a]) is a genetically determined cardiovascular risk factor, causally linked to both atherosclerotic coronary artery disease and aortic valve stenosis. Elevated Lp(a) is widely prevalent, and several cardiovascular societies now recommend performing Lp(a) screening at least once in all adults. While, there are currently no approved drugs aimed specifically at lowering Lp(a), there are several promising Lp(a)-lowering therapies in the drug development pipeline and likely to get approved in the coming months. We... see more